Turkiye Klinikleri Cardiovascular Sciences

.: ORIGINAL RESEARCH
Esansiyel Trombositoz ve Polistemia Vera Tanılı Hastalarda CRP, TNF, VEGF, FGF ve PNTX Kan Düzeylerinin Araştırılması
CRP, TNF, VEGF, FGF and PNTX Blood Levels in Patients with Essential Thrombocytosis and Polistemia Vera
Cengiz CEYLANa, Murat AKŞİTb, Mehmet Can UĞURc, Merve ZEYTİNLİ AKŞİTd, Bilge TAŞKIRANe, Ayfer ÇOLAKf
aHematoloji Kliniği,
eİç Hastalıkları Kliniği,
fTıbbi Biyokimya Kliniği, Sağlık Bilimleri Üniversitesi Tepecik Eğitim ve Araştırma Hastanesi, İzmir, TÜRKİYE
bTıbbi Biyokimya Kliniği, Giresun Üniversitesi Prof. Dr. A. İlhan Özdemir Eğitim ve Araştırma Hastanesi, Giresun, TÜRKİYE
cHematoloji Kliniği, Sağlık Bilimleri Üniversitesi Bozyaka Eğitim ve Araştırma Hastanesi, İzmir, TÜRKİYE
dGiresun Halk Sağlığı Laboratuvarı, Giresun, TÜRKİYE
Turkiye Klinikleri J Cardiovasc Sci. 2019;31(3):143-7
doi: 10.5336/cardiosci.2019-70014
Article Language: TR
Full Text
ÖZET
 Amaç: Kronik miyeloproliferatif hastalıklar (MPN), süreğen bir inflamasyonla birlikte seyreder. Bu süreğen inflamasyon, akut miyeloid lösemiye ilerleme, ikincil maligniteler, tromboemboli ve ikincil inflamatuar hastalıkların gelişimi açısından bir risk faktörü oluşturur. Bu çalışmada, polistemia vera (PV) ve esansiyel trombositoz (ET) tanılı hastalarımızda inflamatuar mediyatörlerin düzeylerini araştırmayı amaçladık. Gereç ve Yöntemler: Çalışmaya 30 PV ve 30 ET hastası, 28 sağlıklı kontrol grubu alındı. Her 3 gruptan TNF, VEGF, FGF, PNTX, CRP, yaş, hemoglobin düzeyi, lökosit ve trombosit sayısı, ET tanılı hastaların CALR, JAK-2, MPL mutasyonu verileri kaydedildi. Veriler istatistiksel yöntemlerle değerlendirildi. Bulgular: PV, ET ve kontrol grubundaki hastaların yaş ortalamaları sırasıyla 63,5, 54,2, 62,7 bulundu. PV hastalarının kontrol grubuna göre CRP değerleri arasında istatistiksel anlamlı farklılık saptanmadı. PV ve ET gruplarının kontrol grubuna göre TNF, FGF, PNTX değerlerinde anlamlı farklılık yoktu. PV grubunun kontrol grubuna göre VEGF değerlerindeki artış istatistiksel olarak anlamlı değildi. Ancak, ET grubunda bu artış anlamlı bulundu (p=0,008). ET grubunda 5 hastada CALR, 15 hastada JAK-2 mutasyonu pozitifti. Hiç MPL mutasyonu saptanmadı. 8 hasta ise üçlü negatif bulundu. CALR, JAK-2 pozitif ve üçlü negatif hastaların TNF, VEGF, FGF, PNTX değerleri arasında istatistiksel anlamlı farklılık yoktu. JAK-2 pozitif saptanan hastaların allel yükü ile CRP değerleri arasında istatistiksel anlamlılık saptandı (p=0,005). Ancak TNF, VEGF, FGF ve PNTX ile istatistiksel anlamlı bir fark yoktu. Sonuç: Süreğen inflamasyon, MPN patogenezi ve klinik seyrinde önemli bir rol oynamaktadır. İnflamatuar mediyatölerlerin MPN'deki rolünün daha net anlaşılabilmesi için daha geniş serilerle randomize kontrollü çalışmalara ihtiyaç vardır.

Anahtar Kelimeler: Esansiyel trombositoz; polistemia vera; inflamasyon
ABSTRACT
 Objective: Chronic myeloproliferative neoplasms (MPN) are associated with chronic inflammation. This chronic inflammation is a risk factor for progression of acute myeloid leukemia, secondary malignancies, thromboembolism and the development of secondary inflammatory diseases. We aimed to investigate the levels of inflammatory mediators in patients with polistemia vera (PV) and essential thrombocytosis (ET). Material and Methods: Thirty patients with PV and 30 ET and 28 healthy controls were included in study. TNF, VEGF, FGF, PNTX, CRP, age, hemoglobin level, leukocyte and platelet count, CALR, JAK-2, MPL mutation of patients with ET were recorded. Data were evaluated by statistical methods. Results: The mean age of the patients in the PV, ET and control groups was 63.5, 54.2, 62.7, respectively. There was no statistically significant difference between the CRP values of the PV patients according to the control group. There was no significant difference in the TNF, FGF and PNTX values of the PV and ET groups compared to the control group. The increase in VEGF values of the PV group compared to the control group was not statistically significant. However, this increase was significant in the ET group (p=0.008). CALR in 5 patients and JAK-2 mutation in 15 patients were positive in the ET group. No MPL mutations were detected. 8 patients were found to be triple negative. There was no statistically significant difference between the TNF, VEGF, FGF, PNTX values of CALR, JAK-2 positive and triple negative patients. A statistically significant difference was found between allele load and CRP values of patients with JAK-2 positive (p=0.005). However, there was no statistically significant difference between TNF, VEGF, FGF and PNTX. Conclusion: Chronic inflammation -lays an important role in the pathogenesis and clinical course of MPN. Randomized controlled trials with larger series are needed to better understand the role of inflammatory mediators in MPN.

Keywords: Essential thrombocytosis; polycythemia vera; ınflammation
REFERENCES:
  1. Mendez Luque LF, Blackmon AL, Ramanathan G, Fleischman AG. Role of inflammation in myeloproliferative neoplasms: instigator of disease initiation, progression and symptoms. Curr Hematol Malig Rep. 2019;14(3):145-53. [Crossref]  [PubMed] 
  2. Kristinsson SY, Bjorkholm M, Hultcrantz M, Derolf AR, Landgren O, Goldin LR. Chronic immune stimulation might act as a trigger for the development of acute myeloid leukemia or myelodysplastic syndromes. J Clin Oncol. 2011;29(21):2897-903. [Crossref]  [PubMed]  [PMC] 
  3. Colotta F, Allavena P, Sica A, Garlanda C, Mantovani A. Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis. 2009;30(7): 1073-81. [Crossref]  [PubMed] 
  4. Marchioli R, Finazzi G, Landolfi R, Kutti J, Gisslinger H, Patrono C, et al. Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. J Clin Oncol. 2005;23(10): 2224-32. [Crossref]  [PubMed] 
  5. Kristinsson SY, Landgren O, Samuelsson J, Bjorkholm M, Goldin LR. Autoimmunity and the risk of myeloproliferative neoplasms. Haematologica. 2010;95(7):1216-20. [Crossref]  [PubMed]  [PMC] 
  6. Barbui T, Carobbio A, Finazzi G, Guglielmelli P, Salmoiraghi S, Rosti V, et al. Elevated C-reactive protein is associated with shortened leukemia-free survival in patients with myelofibrosis. Leukemia. 2013;27(10):2074-6. [Crossref]  [PubMed] 
  7. Kaptoge S, Di Angelantonio E, Lowe G, Pepys MB, Thompson SG, Collins R, et al. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet. 2010;375(9709):132-40. [Crossref] 
  8. Di Raimondo F, Azzaro MP, Palumbo GA, Bagnato S, Stagno F, Giustolisi GM, et al. "Elevated vascular endothelial growth factor (VEGF) serum levels in idiopathic myelofibrosis. Leukemia. 2001;15(6):976-80. [Crossref]  [PubMed] 
  9. Martyre MC, Le Bousse-Kerdiles MC, Romquin N, Chevillard S, Praloran V, Demory JL, et al. Elevated levels of basic fibroblast growth factor in megakaryocytes and platelets from patients with idiopathic myelofibrosis. Br J Haematol. 1997;97(2):441-8. [Crossref]  [PubMed] 
  10. Martyre MC, Romquin N, Le Bousse-Kerdiles MC, Chevillard S, Benyahia B, Dupriez B, et al. Transforming growth factor-beta and megakaryocytes in the pathogenesis of idiopathic myelofibrosis. Br J Haematol. 1994;88(1):9-16. [Crossref]  [PubMed] 
  11. Lussana F, Rambaldi A. Inflammation and myeloproliferative neoplasms. J Autoimmun. 2017;85:58-63. [Crossref]  [PubMed] 
  12. Geyer HL, Dueck AC, Scherber RM, Mesa RA. Impact of inflammation on myeloproliferative neoplasm symptom development. Mediators of Inflammation. 2015;9. [Crossref]  [PubMed]  [PMC] 
  13. Dinarello CA. Historical insights into cytokines. Eur J Immunol. 2007;37 Suppl 1:S34-45. [Crossref]  [PubMed]  [PMC] 
  14. Barbui A, Carobbio A, Finazzi G, Vannucchi AM, Barosi G, Antonioli E, et al. Inflammation and thrombosis in essential thrombocythemia and polycythemia vera: different role of C-reactive protein and pentraxin 3. Haematologica. 2011;96(2):315-8. [Crossref]  [PubMed]  [PMC] 
  15. Medinger M, Passweg J. Role of tumour angiogenesis in haematological malignancies. Swiss Med Wkly. 2014;144:w14050. [Crossref] 
  16. Alonci A, Allegra A, Bellomo G, Penna G, D'Angelo A, Quartarone E, et al. Evaluation of circulating endothelial cells, VEGF and VEGFR2 serum levels in patients with chronic myeloproliferative diseases. Hematol Oncol. 2008;26(4):235-9. [Crossref]  [PubMed] 
  17. Musolino C, Calabro' L, Bellomo G, Martello F, Loteta B, Pezzano C, et al. Soluble angiogenic factors: implications for chronic myeloproliferative disorders. Am J Hematol. 2002;69(3):159-63. [Crossref]  [PubMed] 
  18. Vaidya R, Gangat N, Jimma T, Finke CM, Lasho TL, Pardanani A, et al. Plasma cytokines in polycythemia vera: phenotypic correlates, prognostic relevance, and comparison with myelofibrosis. Am J Hematol. 2012;87(11):1003-5. [Crossref]  [PubMed] 
  19. Lev PR, Marta RF, Vassallu P, Molinas FC. Variation of PDGF, TGFbeta, and bFGF levels in essential thrombocythemia patients treated with anagrelide. Am J Hematol. 2002;70(2):85-91. [Crossref]  [PubMed] 
  20. Tefferi A, Vaidya R, Caramazza D, Finke C, Lasho T, Pardanani A. Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study. J Clin Oncol. 2011;29(10):1356-63. [Crossref]  [PubMed] 
  21. Pourcelot E, Trocme C, Mondet J, Bailly S, Toussaint B, Mossuz P. Cytokine profiles in polycythemia vera and essential thrombocythemia patients: clinical implications. Exp Hematol. 2014;42(5):360-8. [Crossref]  [PubMed] 
  22. Lussana F, Carobbio A, Salmoiraghi S, Guglielmelli P, Vannucchi AM, Bottazzi B, et al. Driver mutations (JAK2V617F, MPLW515L/K or CALR), pentraxin-3 and C-reactive protein in essential thrombocythemia and polycythemia vera. J Hematol Oncol. 2017;10(1):54. [Crossref]  [PubMed]  [PMC] 

.: Up To Date

.: Process List

Login

 Forgot your password?

 New Registration  

Contact

Ortadoğu Reklam Tanıtım Yayıncılık Turizm Eğitim İnşaat Sanayi ve Ticaret A.Ş.

.: Address

Turkocagi Caddesi No:30 06520 Balgat / ANKARA
Phone: +90 312 286 56 56
Fax: +90 312 220 04 70
E-mail: info@turkiyeklinikleri.com

.: Manuscript Editing Department

Phone: +90 312 286 56 56/ 2
E-mail: yaziisleri@turkiyeklinikleri.com

.: English Language Redaction

Phone: +90 312 286 56 56/ 145
E-mail: tkyayindestek@turkiyeklinikleri.com

.: Marketing Sales-Project Department

Phone: +90 312 286 56 56/ 142
E-mail: reklam@turkiyeklinikleri.com

.: Subscription and Public Relations Department

Phone: +90 312 286 56 56/ 118
E-mail: abone@turkiyeklinikleri.com

.: Customer Services

Phone: +90 312 286 56 56/ 118
E-mail: satisdestek@turkiyeklinikleri.com

1. TERMS OF USE

1.1. To use the web pages with http://www.turkiyeklinikleri.com domain name or the websites reached through the sub domain names attached to the domain name (They will be collectively referred as "SITE"), please read the conditions below. If you do not accept these terms, please cease to use the "SITE." "SITE" owner reserves the right to change the information on the website, forms, contents, the "SITE," "SITE" terms of use anytime they want.

1.2. The owner of the "SITE" is Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. (From now on it is going to be referred as "Turkiye Klinikleri", shortly) and it resides at Turkocagi cad. No:30, 06520 Balgat Ankara. The services in the "SITE" are provided by "Turkiye Klinikleri."

1.3. Anyone accessing the "SITE" with or without a fee whether they are a natural person or a legal identity is considered to agree these terms of use. In this contract hereby, "Turkiye Klinikleri" may change the stated terms anytime. These changes will be published in the "SITE" periodically and they will be valid when they are published. Any natural person or legal identity benefiting from and reaching to the "SITE" are considered to be agreed to any change on hereby contract terms done by "Turkiye Klinikleri."

1.4. The "Terms of Use" hereby is published in the website with the last change on March 30th 2014 and the "SITE" is activated by enabling the access to everyone. The "Terms of Use" hereby is also a part of the any "USER Contract" was and/or will be done with the users using "Turkiye Klinikleri" services with or without a fee an inseparable.

2. DEFINITIONS

2.1. "SITE": A website offering different kind of services and context with a certain frame determined by "Turkiye Klinikleri" and it is accessible on-line on http://www.turkiyeklinikleri.com domain name and/or subdomains connected to the domain name.

2.2. USER: A natural person or a legal identity accessing to the "SITE" through online settings.

2.3. LINK: A link enabling to access to another website through the "SITE", the files, the context or through another website to the "SITE", the files and the context.

2.4. CONTEXT: Any visual, literary and auditory images published in the "Turkiye Klinikleri", "SITE" and/or any website or any accessible information, file, picture, number/figures, price, etc.

2.5. "USER CONTRACT": An electronically signed contract between a natural or a legal identity benefiting from special services "Turkiye Klinikleri" will provide and "Turkiye Klinikleri".

3. SCOPE OF THE SERVICES

3.1. "Turkiye Klinikleri" is completely free to determine the scope and quality of the services via the "SITE".

3.2. To benefit the services of "Turkiye Klinikleri" "SITE", the "USER" must deliver the features that will be specified by "Turkiye Klinikleri". "Turkiye Klinikleri" may change this necessity any time single-sided.

3.3. Not for a limited number, the services "Turkiye Klinikleri" will provide through the "SITE" for a certain price or for free are;

- Providing scientific articles, books and informative publications for health industry.

- Providing structural, statistical and editorial support to article preparation stage for scientific journals.

4. GENERAL PROVISIONS

4.1. "Turkiye Klinikleri" is completely free to determine which of the services and contents provided in the "SITE" will be charged.

4.2. People benefiting from the services provided by "Turkiye Klinikleri" and using the website can use the "SITE" only according to the law and only for personal reasons. Users have the criminal and civil liability for every process and action they take in the "SITE". Every USER agrees, declares and undertakes that they will not proceed by any function or action infringement of rights of "Turkiye Klinikleri"s and/or other third parties', they are the exclusive right holder on usage, processing, storage, made public and revealing any written, visual or auditory information reported to Turkiye Klinikleri" and/or "SITE" to the third parties. "USER" agrees and undertakes that s/he will not duplicate, copy, distribute, process, the pictures, text, visual and auditory images, video clips, files, databases, catalogs and lists within the "SITE", s/he will not be using these actions or with other ways to compete with "Turkiye Klinikleri", directly or indirectly.

4.3. The services provided and the context published within the "SITE" by third parties is not under the responsibility of "Turkiye Klinikleri", institutions collaborated with "Turkiye Klinikleri", "Turkiye Klinikleri" employee and directors, "Turkiye Klinikleri" authorized salespeople. Commitment to accuracy and legality of the published information, context, visual and auditory images provided by any third party are under the full responsibility of the third party. "Turkiye Klinikleri" does not promise and guarantee the safety, accuracy and legality of the services and context provided by a third party.

4.4. "USER"s cannot act against "Turkiye Klinikleri", other "USER"s and third parties by using the "SITE". "Turkiye Klinikleri" has no direct and/or indirect responsibility for any damage a third party suffered or will suffer regarding "USER"s actions on the "SITE" against the rules of the hereby "Terms of Use" and the law.

4.5. "USER"s accept and undertake that the information and context they provided to the "SITE" are accurate and legal. "Turkiye Klinikleri" is not liable and responsible for promising and guaranteeing the verification of the information and context transmitted to "Turkiye Klinikleri" by the "USER"s, or uploaded, changed and provided through the "SITE" by them and whether these information are safe, accurate and legal.

4.6. "USER"s agree and undertake that they will not perform any action leading to unfair competition, weakening the personal and commercial credit of "Turkiye Klinikleri" and a third party,  encroaching and attacking on personal rights within the "SITE" in accordance with the Turkish Commercial Code Law.

4.7. "Turkiye Klinikleri" reserves the right to change the services and the context within the "SITE"  anytime. "Turkiye Klinikleri" may use this right without any notification and timelessly. "USER"s have to make the changes and/or corrections "Turkiye Klinikleri" required immediately. Any changes and/or corrections that are required by "Turkiye Klinikleri", may be made by "Turkiye Klinikleri" when needed. Any harm, criminal and civil liability resulted or will result from changes and/or corrections required by "Turkiye Klinikleri" and were not made on time by the "USER"s belongs completely to the users.

4.8. "Turkiye Klinikleri" may give links through the "SITE" to other websites and/or "CONTEXT"s and/or folders that are outside of their control and owned and run by third parties. These links are provided for ease of reference only and do not hold qualification for support the respective web SITE or the admin or declaration or guarantee for the information inside. "Turkiye Klinikleri" does not hold any responsibility over the web-sites connected through the links on the "SITE", folders and context, the services or products on the websites provided through these links or their context.

4.9. "Turkiye Klinikleri" may use the information provided to them by the "USERS" through the "SITE" in line with the terms of the "PRIVACY POLICY" and "USER CONTRACT". It may process the information or classify and save them on a database. "Turkiye Klinikleri" may also use the USER's or visitor's identity, address, e-mail address, phone number, IP number, which sections of the "SITE" they visited, domain type, browser type, date and time information to provide statistical evaluation and customized services.

5. PROPRIETARY RIGHTS

5.1. The information accessed through this "SITE" or provided by the users legally and all the elements (including but not limited to design, text, image, html code and other codes) of the "SITE" (all of them will be called as studies tied to "Turkiye Klinikleri"s copyrights) belongs to "Turkiye Klinikleri". Users do not have the right to resell, process, share, distribute, display or give someone permission to access or to use the "Turkiye Klinikleri" services, "Turkiye Klinikleri" information and the products under copyright protection by "Turkiye Klinikleri". Within hereby "Terms of Use" unless explicitly permitted by "Turkiye Klinikleri" nobody can reproduce, process, distribute or produce or prepare any study from those under "Turkiye Klinikleri" copyright protection.

5.2. Within hereby "Terms of Use", "Turkiye Klinikleri" reserves the rights for "Turkiye Klinikleri" services, "Turkiye Klinikleri" information, the products associated with "Turkiye Klinikleri" copyrights, "Turkiye Klinikleri" trademarks, "Turkiye Klinikleri" trade looks or its all rights for other entity and information it has through this website unless it is explicitly authorized by "Turkiye Klinikleri".

6. CHANGES IN THE TERMS OF USE

"Turkiye Klinikleri" in its sole discretion may change the hereby "Terms of Use" anytime announcing within the "SITE". The changed terms of the hereby "Terms of Use" will become valid when they are announced. Hereby "Terms of Use" cannot be changed by unilateral declarations of users.

7. FORCE MAJEURE

"Turkiye Klinikleri" is not responsible for executing late or never of this hereby "Terms of Use", privacy policy and "USER Contract" in any situation legally taken into account as force majeure. Being late or failure of performance or non-defaulting of this and similar cases like this will not be the case from the viewpoint of "Turkiye Klinikleri", and "Turkiye Klinikleri" will not have any damage liability for these situations. "Force majeure" term will be regarded as outside of the concerned party's reasonable control and any situation that "Turkiye Klinikleri" cannot prevent even though it shows due diligence. Also, force majeure situations include but not limited to natural disasters, rebellion, war, strike, communication problems, infrastructure and internet failure, power cut and bad weather conditions.

8. LAW AND AUTHORISATION TO FOLLOW

Turkish Law will be applied in practicing, interpreting the hereby "Terms of Use" and managing the emerging legal relationships within this "Terms of Use" in case of finding element of foreignness, except for the rules of Turkish conflict of laws. Ankara Courts and Enforcement Offices are entitled in any controversy happened or may happen due to hereby contract.

9. CLOSING AND AGREEMENT

Hereby "Terms of Use" come into force when announced in the "SITE" by "Turkiye Klinikleri". The users are regarded to agree to hereby contract terms by using the "SITE". "Turkiye Klinikleri" may change the contract terms and the changes will be come into force by specifying the version number and the date of change on time it is published in the "SITE".

 

30.03.2014

Privacy Policy

We recommend you to read the terms of use below before you visit our website. In case you agree these terms, following our rules will be to your favor. Please read our Terms of Use thoroughly.

www.turkiyeklinikleri.com website belongs to Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. and is designed in order to inform physicians in the field of health

www.turkiyeklinikleri.com cannot reach to user’s identity, address, service providers or other information. The users may send this information to the website through forms if they would like to. However, www.turkiyeklinikleri.com may collect your hardware and software information. The information consists of your IP address, browser type, operating system, domain name, access time, and related websites. www.turkiyeklinikleri.com cannot sell the provided user information (your name, e-mail address, home and work address, phone number) to the third parties, publish it publicly, or keep it in the website. Gathered information has a directing feature to be a source for the website’s visitor profile, reporting and promotion of the services.

www.turkiyeklinikleri.com uses the taken information:

-To enhance, improve and maintain the quality of the website

-To generate visitor’s profile and statistical data

-To determine the tendency of the visitors on using our website

-To send print publications/correspondences

-To send press releases or notifications through e-mail

-To generate a list for an event or competition

By using www.turkiyeklinikleri.com you are considered to agree that;

-Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. cannot be hold responsible for any user’s illegal and immoral behavior,

-Terms of use may change from time to time,

-It is not responsible for other websites’ contents it cannot control or the harms they may cause although it uses the connection they provided.

Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. may block the website to users in the following events:

-Information with wrong, incomplete, deceiving or immoral expressions is recorded to the website,

-Proclamation, advertisement, announcement, libelous expressions are used against natural person or legal identity,

-During various attacks to the website,

-Disruption of the website because of a virus.

Written, visual and audible materials of the website, including the code and the software are under protection by legal legislation.

Without the written consent of Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. the information on the website cannot be downloaded, changed, reproduced, copied, republished, posted or distributed.

All rights of the software and the design of the website belong to Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc.

Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. will be pleased to hear your comments about our terms of use. Please share the subjects you think may enrich our website or if there is any problem regarding our website.

info@turkiyeklinikleri.com